



Alvaiz (eltrombopag)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF](https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Alvaiz (eltrombopag)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> Chronic hepatitis C <input type="checkbox"/> Immune (idiopathic) thrombocytopenic purpura (ITP) <input type="checkbox"/> Aplastic Anemia <input type="checkbox"/> Other diagnosis: _____ ICD-10: _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p>Will patient be using Alvaiz (eltrombopag) in combination with a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have an absolute contraindication to Promacta tablets? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For <u>chronic hepatitis C</u>, answer the following: Is the patient's platelet count between 20,000/mcL and 70,000/mcL?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit documentation.</i></p> <p>Is Alvaiz prescribed by a gastroenterology or hematology/oncology specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For <u>INITIAL Request of immune (idiopathic) thrombocytopenic purpura (ITP)</u>, answer the following: Is Alvaiz prescribed by a hematology/oncology specialist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Is the patient's platelet count less than 30,000/mcL OR greater than or equal to 30,000/mcL with additional risk factors for bleeding? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit documentation.</i></p> <p>Please submit with chart notes the exact month and year that patient was diagnosed with immune (idiopathic) thrombocytopenic purpura (ITP) _____</p> <p>For newly diagnosed primary ITP, is the request for Alvaiz (eltrombopag) within 3 months since the initial date of diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For persistent primary ITP, is the request for Alvaiz (eltrombopag) 3 to 12 months since the initial date of diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>For chronic persistent relapsed primary ITP, is the request for Alvaiz (eltrombopag) greater than or equal to 12 months since the initial diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Have all other causes of secondary ITP been ruled out such as: Inherited thrombocytopenia, Myelodysplastic Syndrome, HIV, HCV, CLL, drug-induced immune thrombocytopenia, SLE, RA, common variable immune deficiency</p>		





MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

(COVID), Helicobacter pylori infection, CMV, selective IgA deficiency, autoimmune lymphoproliferative syndrome (ALPS)? Yes No

Has the patient had an insufficient response, intolerance or absolute contraindication to corticosteroids?* Yes No **Please submit documentation.*

Has the patient had an insufficient response, intolerance or absolute contraindication to immunoglobulins (IVIG)?* Yes No **Please submit documentation.*

Has the patient had an insufficient response, intolerance or absolute contraindication to rituximab?* Yes No **Please submit documentation.*

Has the patient had a splenectomy with an inadequate response? Yes No

If "no" to the above question, does the patient have an absolute contraindication to splenectomy?* Yes No **Please submit documentation which includes surgeon or anesthesiologist consultation.*

If "yes" to the above question, has the patient had an insufficient response or intolerance to post-splenectomy corticosteroids?* Yes No **Please submit documentation.*

For patients over 61 years of age, do the results from the most recent bone marrow aspiration show evidence of myelodysplasia as a possible cause for thrombocytopenia?* Yes No **Please submit documentation.*

For RENEWAL Request of immune (idiopathic) thrombocytopenic purpura (ITP):

Is patient continuing to have a positive clinical response? Yes No **Please submit documentation.*

Has the patient had a splenectomy with an inadequate response? Yes No

If "no" to the above question, does the patient have an absolute contraindication to splenectomy?* Yes No **Please submit documentation which includes surgeon or anesthesiologist consultation.*

For Aplastic Anemia:

Does patient have an Absolute neutrophil count less than or equal to 500/microliter? Yes No **Please submit documentation.*

Does patient have a Platelet count less than 20,000/microliter? Yes No **Please submit documentation.*

Does patient have an Absolute reticulocyte count less than 60,000/microliter? Yes No **Please submit documentation.*

Does patient have Fanconi's anemia? Yes No

Does patient have an SGOT or SGPT more than 5 times the upper limit of normal? Yes No **Please submit documentation.*

Does patient have a clonal disorder consistent with myelodysplasia? Yes No

Is patient 2 years of age or older? Yes No

If yes, does patient weigh more than 12 kg? Yes No





Alvaiz (eltrombopag)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

If yes, has the patient received treatment for severe aplastic anemia? Yes No

Is patient 18 years of age or older? Yes No

If yes, has patient had insufficient response to immunosuppressive therapy for severe aplastic anemia? Yes No
**Please submit documentation.*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811

